Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus, Inc. (NASDAQ: EOLS) announced the appointment of Christos Monovoukas as Senior Vice President of Corporate Development, effective February 28, 2022. Monovoukas has over 20 years of experience in business development, previously serving at Olympus Corporation and Smith & Nephew. In connection with his hiring, Evolus granted him inducement awards consisting of options for 171,103 shares and 39,012 RSUs, with an exercise price of $9.15. CEO David Moatazedi expressed confidence in Monovoukas' ability to support the company's growth strategy.
Evolus, Inc. (NASDAQ: EOLS) announced it will report its fourth quarter and year-end 2021 financial results on March 3, 2022, after U.S. market close. A conference call and live webcast will follow at 4:30 p.m. ET, including a Q&A session. Participants can join via phone or through the Evolus website. A replay of the call will be available after completion. Evolus, known for its neurotoxin Jeuveau®, focuses on redefining the aesthetic market with innovative customer-centric products.
Evolus, Inc. (NASDAQ: EOLS) has announced that its submission for regulatory approval of Nuceiva® (prabotulinumtoxinA) has been accepted by the Australian Therapeutics Good Administration (TGA). This is a significant milestone for the company's international growth strategy, as Australia represents one of the largest global markets for aesthetics. Nuceiva® is already approved in the U.S. as Jeuveau®, and in Europe and Canada. Evolus aims to complete the TGA approval process in 2023 and plans to launch Nuceiva® in select European countries later this year.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, announced participation in the Virtual 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, from 4:20 PM to 4:50 PM ET. The event will showcase Evolus' focus on delivering breakthrough products, including its FDA-approved neurotoxin, Jeuveau®. Interested parties can access an audio webcast on the investor relations section of Evolus’ website, with a replay available for 90 days.
Evolus, Inc. (NASDAQ: EOLS) reported preliminary unaudited net revenues of approximately $34.7 million for Q4 2021, marking a 68% increase from the previous year. For full-year 2021, total net revenues reached approximately $99.7 million, a 76% growth over 2020. The company expects 2022 revenues between $143 million and $150 million, anticipating growth of 43% to 50%. As of December 31, 2021, Evolus maintains a strong cash position of $146.3 million. The company plans to enhance market presence and launch new products in 2022.
Evolus, Inc. (NASDAQ: EOLS) has appointed Brady Stewart, a digital and beauty innovator, to its Board of Directors, enhancing its leadership team. Stewart brings over 20 years of experience in digital innovation and direct-to-consumer strategies, currently serving as Chief Commercial Officer at Forma Brands. The Chairman, Vikram Malik, emphasized her potential contribution as the company aims to be a leading multi-product aesthetics company. Stewart expressed her excitement to join at a pivotal moment, highlighting the potential of the company's product, Jeuveau®, in transforming the aesthetic neurotoxin industry.
Tenaya Therapeutics (NASDAQ: TNYA) announced two key appointments: Karah Parschauer to its Board of Directors and Joanna Auch as Senior VP of People and Culture. These appointments aim to strengthen Tenaya's leadership amid its transition to a public company with over 100 employees. CEO Faraz Ali highlighted that both individuals bring valuable experience and will enhance the company's capabilities in drug development for heart disease. Parschauer has extensive biopharmaceutical experience and previously held roles at Ultragenyx, while Auch has over 15 years in HR.
Evolus, Inc. (NASDAQ: EOLS) has been added to the Nasdaq Biotechnology Index (NBI) as part of its annual reconstitution. This inclusion is expected to enhance Evolus' visibility and shareholder base. CFO Lauren Silvernail indicated that robust sales and market share gains position the company for a strong finish in 2021 and growth in 2022. Evolus focuses on innovative aesthetic products, particularly Jeuveau®, a neurotoxin exclusively for aesthetics, approved in 2019 by the FDA.
Evolus, Inc. (NASDAQ: EOLS) has secured a $125 million term loan financing with Pharmakon Advisors, L.P. This facility includes an initial draw of $75 million to support corporate purposes and achieve cash flow breakeven. A second $50 million draw is available before December 31, 2022, providing potential for strategic transactions. The loan matures in six years with interest-only payments for the first 39 months. The CEO emphasizes this funding strengthens their capital structure and supports growth in the aesthetic neurotoxin market.
Evolus, Inc. (NASDAQ: EOLS) announced the participation of its management team in two investment conferences this November. The first event is the Stifel 2021 Virtual Healthcare Conference on November 16 at 2:40 pm ET. The second is the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30 at 7:30 am ET. Audio webcasts of both events will be available on Evolus' investor relations website for 90 days following the presentations. Evolus specializes in aesthetic products, including Jeuveau®, the first neurotoxin solely for aesthetics.